1. Revenue from operations stood at ₹860 Cr attributing to growth of 95% YoY
2. EBITDA stood at ₹118.7 Cr with EBITDA margins at 14%
3. Bounce back from the setback caused due to floods in previous quarter
4. Import duty on prime raw material “acetic acid” is now reduced from 7.5% to 5% which will have favourable impact on raw material cost
5. India is a very small producer of acetic acid and one of the large consumer globally
Segmental review
Specialty intermediates
1. Business contributed 30% of the top line.
2. The robust performance of speciality intermediates is attributed to ramped up production, following the flood restoration, increased
realisations and better product mix optimization towards high value added products
3. Exports contribute 30% of Speciality intermediates sales which was less than 10% in previous years
4. Raw material prices are correcting and margin visibility is sustainable
5. Capacity utilisation at 70% for 9MFY22
Acetyl intermediates
1. Business contributed 62% of the top line.
2. The strong growth on account of increased realisations and high volumes supported by the subsidiary capacity (Yellowstone Pvt Ltd)
3. The prices in the overseas market remain strong through most part of quarter specially in Europe
4. The volume growth is sustainable in future, given that the raw material prices correcting and commodity cycles are normalising, expansion in margins could be expected
Capacity utilisation at 80% for 9MFY22
Capex
1. Initial capex was ₹280-₹290 Cr, now it's reassessed value is ₹450Cr. Part of this incremental cost is time overrun, escalation in cost and significant part of it is increasing infrastructure for
capacities of new and existing products
2. On track to commercialise speciality intermediates projects and these will start clocking in revenues from Q1FY23
3. Decision on launching phase 2 capacity of fluoro chemicals to add incremental capacities. It will be commercialised in Q3FY23
4. Expected turnover in fluorochemicals is ₹280-₹300 Cr
5. One in every 3 new APIs will be based on fluorine chemistry
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment.
2. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market.
1. They have had a very strong quarter - especially in CRAMS where the pipeline continues to be very strong.
2. They are seeing good interest and strong growth in the Vitamin D analogues.
3. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers.
4. They have seen a rapid rise in transportation and logistics costs. There are also price rises in Central Europe for basic utilities like electricity, gas and water.
1. Revenues stood at ₹475 Cr in Q3FY22 compared to ₹366 Cr in Q3FY21, growth of 29.4% YoY
2. EBITDA stood at 109.3 Cr translating 23% EBITDA margins
3. Sales volumes were down by 13.77% from 31,993 MT in Q3FY21 to 27,589 MT in Q3FY22. As few of the clients couldn’t procure Key Starting Materials (KSMs) to match the products.
4. Despite sluggish demand for few of the products and shut down of acetonitrile and DMF plants for debottlenecking which were completed in the month of November 2021, the revenues showed a decent growth of 44% which stood at ₹556 Cr in Q3FY22
1. Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%.
2. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments viz. anti-infectives, gastrointestinal, urological and respiratory performed well.